Researchers Race to Design the First Treatments Specifically for NeuroAIDS

Experimental drugs are showing promise against neuroAIDS, the nerve damage caused by HIV infection that lessens many patients’ ability to think and move. As evidence of the progress, researchers at the University of Rochester Medical Center today received a $7 million grant to confirm that two new drug classes can protect the brain from HIV-related nerve damage. Driving their approach is the realization that antiviral drugs that work against AIDS do not cure neuroAIDS.